A significant global research initiative is underway to develop a convenient blood test for diagnosing Alzheimer’s disease. The study focuses on three specific proteins linked to the condition, aiming to compare the efficacy of the test with current brain scans. If successful, this new test could offer a simpler alternative to existing diagnostic methods like scans, lumbar punctures, and spinal taps. Utilizing a plasma separation card, the finger prick test would leverage digital biomarkers to expedite Alzheimer’s diagnosis, potentially enabling earlier intervention at a lower cost.
The research is part of the Global Alzheimer’s Platform Foundation (GAP) Bio-Hermes-002 study, supported by the non-profit organization LifeArc. Nearly 883 out of the required 1,000 volunteers have already been enrolled from various sites in the UK, USA, and Canada. The participants include individuals at different stages of the disease, ranging from asymptomatic to mild cognitive impairment and mild to moderate Alzheimer’s.
Dr. Giovanna Lalli, Director of Strategy and Operations at LifeArc, emphasized the importance of developing accessible and affordable tests to combat Alzheimer’s disease effectively. She expressed optimism about the potential of a finger-prick blood test to improve patient access to early-stage disease treatments. John Dwyer, President of GAP, highlighted the transformative impact a simple blood test could have on diagnosis, noting the need for further refinement post-trial completion.
Prof Henrik Zetterberg, Lead of the Biomarker Factory at the UK Dementia Research Institute, stressed the significance of comparing the new test results against current diagnostic standards. If successful, the minimally invasive and cost-effective diagnostic method could revolutionize Alzheimer’s diagnosis and pave the way for enhanced detection of neurodegenerative conditions.
The research trial is set to conclude in 2028, with an estimated 944,000 dementia cases in the UK and around seven million in the US. Alzheimer’s, affecting six in 10 dementia patients, manifests with memory loss, reasoning challenges, and language difficulties as initial symptoms. Recent analysis by Alzheimer’s Research UK revealed an increase in dementia-related deaths in the UK, making it the leading cause of mortality in the country.
By opting for Daily Mirror as a ‘Preferred Source’ on Google News, users can access valuable news content conveniently.